Details of the Drug Combination

General Information of Drug Combination (ID: DC76PHF)

• Drug Combination Name: Azatadine + BIO-300
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  Azatadine (DMZ80SB): Small molecular drug
  BIO-300 (DMJ7NVI): N.A.
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 1.08
  Bliss Independence Score: 1.08
  Loewe Additivity Score: 1.72
  LHighest Single Agent (HSA) Score: 1.75

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Azatadine

Disease Entry	ICD 11	Status	REF
Allergic rhinitis	CA08.0	Approved	[2]
Common cold	CA00	Approved	[3]
Seasonal allergic rhinitis	CA08.01	Approved	[3]
Urticaria	EB00-EB05	Approved	[3]
Vasomotor/allergic rhinitis	CA08	Approved	[3]
Pruritus	EC90	Investigative	[3]

Azatadine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Antagonist	[6]

Indication(s) of BIO-300

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]
Rheumatoid arthritis	FA20	Phase 1	[5]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7119).
• [3] Azatadine FDA Label
• [4] Clinical pipeline report, company report or official report of Humanetics.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis. Asian Pac J Allergy Immunol. 1990 Dec;8(2):103-7.